Objective To detect the expressions of CK5/6 and Ki-67 in breast cancer， and explore the clinical significance. Methods The expressions of CK5/6 and Ki-67 were detected by immunohistochemistry in 162 cases of breast cancer . The correlation between CK5/6 expression and Ki-67 expression and the relationship of the expressions of two factors to the clinicopathologic factors were analyzed. Results There were 12 cases of the triple negative breast cancer 〔negative estrogen receptor （ER）， negative progesterone receptor （PR）， and negative Her-2〕 in 162 patients with breast cancer. The positive rates of CK5/6 and Ki-67 in the breast cancer tissues were 30.9% （50/162） and 65.4% （106/162），respectively. The positive rates of CK5/6 and Ki-67 in the patients with triple negative breast cancer were significantly higher than those of non-triple negative breast cancer 〔CK5/6：75.0% （9/12） versus 27.3% （41/150）， χ2=11.837， P=0.001；Ki-67：100% （12/12） versus 62.7% （94/150）， χ2=6.847， P=0.009〕. The expressions of CK5/6 and Ki-67 in the breast cancer tissues were not associated with age （P＞0.05）， but they were associated with histology grade （P＜0.05）. The expression of CK5/6 wasn’t associated with tumor size and lymph node status （P＞0.05）， but the expression of Ki-67 was associated with them （P＜0.05）. The expression of CK5/6 in the breast cancer tissue had a positive correlation with the expression of Ki-67 in the breast cancer tissue （rs=0.271， P=0.000）. There were 64 cases when the expression of Ki-67 was （＋＋） and （＋＋＋）， the positive rate of CK5/6 was 43.8% （28/64） and it was significantly higher than that when the expression of Ki-67 was （-） and （＋） 〔22.4% （22/98）， χ2=8.233， P=0.004〕. The positive expressions of CK5/6 and Ki-67 in the breast cancer tissues were negatively correlated with the expressions of ER and PR （CK5/6 and ER：rs=-0.446， P=0.000；CK5/6 and PR：rs=-0.370， P=0.000；Ki-67 and ER：rs=-0.518， P=0.000；Ki-67 and PR：rs=-0.515， P=0.000）. The positive expressions of CK5/6 and Ki-67 in the breast cancer tissue were not correlated with the Her-2 expression （CK5/6 and Her-2：rs=0.105， P=0.183；Ki-67 and Her-2：rs=0.068， P=0.393）. Conclusion The expressions of CK5/6 and Ki67 not only can evaluate the basic rules of breast cancer from origin and development， but also they are beneficial to choose the chemotherapy of different patients.
目的 探讨甲状腺乳头状癌术后复发的相关影响因素，为降低再手术风险及提高临床疗效提供依据。方法 回顾性分析大连医科大学附属第二医院2005年1月至2008年12月期间收治的206例甲状腺乳头状癌患者的临床资料。本组患者均获访3～5年，平均4.1年，采用单因素及多因素分析方法对甲状腺乳头状癌术后复发与患者性别、年龄、肿瘤大小、甲状腺包膜有无浸润、淋巴结有无转移以及手术方式的相关性进行分析。结果 206例甲状腺乳头状癌患者中，术后复发18例。单因素分析结果显示，术后复发与患者性别、肿瘤大小、甲状腺包膜是否被浸润、手术方式及淋巴结转移情况均有关（P＜0.05）；多因素分析结果显示，肿瘤大小、淋巴结转移情况及手术方式与甲状腺乳头状癌术后复发密切相关。结论 肿瘤直径越大、有淋巴结转移和手术切除范围不足可能是甲状腺乳头状癌术后复发的高危因素。
Objective To study the expression of human epidermal growth factor receptor-3 （HER-3） in breast cancer patients and analyze the relation between its expression and the clinical pathology of breast cancer. Methods The complete data of 139 female breast cancer patients underwent operation from January 2006 to October 2006 in this hospital were collected，who were without preoperative chemotherapy and radiation therapy，but with postoperative endo-crine therapies. HER-3 expression in the breast cancer tissues was detected by immunohistochemistry. Information on histological grading，tumor diameter，lymph node metastasis，and telephone number were obtained from their medical records. The relation between indication and HER-3 expression was analyzed. Results ①The positive expression of HER-3 in the breast cancer tissues was 30.2% （42/139）；②The expression of HER-3 was unrelated to the age of patient with breast cancer （r=0.030，P=0.721）；③HER-3 expression was a positive related to the tumor diameter （r=0.176，P=0.038）， lymph node metastasis （r=0.205，P=0.016），or histological grading （r=0.197，P=0.020），which was a negative related to the five-year survival rate （r=-0.254，P=0.003）. Conclusion Detection of HER-3 expression in breast cancer tissues might be a clinical significance for the early diagnosis/treatment，medication，and prognosis of the tumors as well as research and development of new drug.